跳转至内容
Merck
CN

SML0263

Sigma-Aldrich

PF-04217903

≥98% (HPLC)

别名:

4-[1-(6-Quinolinylmethyl)-1H-1,2,3-triazolo[4,5-b]pyrazin-6-yl]-1H-pyrazole-1-ethanol methanesulfonate (1:1)

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C19H16N8O·CH3SO3H
分子量:
468.49
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: ≥5 mg/mL (warmed)

储存温度

2-8°C

SMILES字符串

CS(O)(=O)=O.OCCn1cc(cn1)-c2cnc3nnn(Cc4ccc5ncccc5c4)c3n2

InChI

1S/C19H16N8O.CH4O3S/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16;1-5(2,3)4/h1-5,8-10,12,28H,6-7,11H2;1H3,(H,2,3,4)

InChI key

HBEMHKVWZJTVOC-UHFFFAOYSA-N

基因信息

human ... MET(4233)

应用

PF-04217903 has been used as tyrosine-protein kinase Met (C-Met) selective inhibitor in Madin-Darby Canine kidney (MDCK) cells and NT2D1 non-seminoma cells.

生化/生理作用

PF-04217903 is a highly selective, potent inhibitor of the hepatocyte growth factor receptor c-Met. PF-04217903 inhibits endogenous, wild type c-Met in A549 human lung carcinoma cells with an IC50 of 4.8 nM. The compund displays 1000-fold selectivity against a panel of 208 other kinases.
PF-04217903 is an ATP-competitive inhibitor. It elicits antiangiogenic functionality. PF-04217903 inhibits c-Met phosphorylation in xenograft models leading to partial tumor growth suppression.

特点和优势

This compound is featured on the Met page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

c-MET receptor as potential biomarker and target molecule for malignant testicular germ cell tumors
Scheri K, et al.
Testing, 9(61), 31842-31842 (2018)
c-Src Recruitment is Involved in c-MET-Mediated Malignant Behaviour of NT2D1 Non-Seminoma Cells
Leonetti E, et al.
International Journal of Molecular Sciences, 20(2), 320-320 (2019)
Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor
Zou HY, et al.
Molecular Cancer Therapeutics, 11(4), 1036-1047 (2012)
Erica Leonetti et al.
International journal of molecular sciences, 20(2) (2019-01-17)
: c-MET pathway over-activation is the signature of malignancy acquisition or chemotherapy resistance of many cancers. We recently demonstrated that type II Testicular Germ Cell Tumours (TGCTs) express c-MET receptor. In particular, we elucidated that the non-seminoma lesions express c-MET

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门